Sign In
30 Jan 2017 10:50
Shield Therapeutics plc
("Shield" or the "Group")
Directorate and Secretarial Update
London, UK, 30 January 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces the resignation of Richard Jones as a director and company secretary of the company on 27 January 2017.
The company had previously announced on 7 November 2016 that Richard Jones would leave the Group in early 2017 to pursue a new opportunity.
The company has appointed Capita Registrars Limited as company secretary from 27 January 2017.
- Ends -
For further information please contact:
Shield Therapeutics plc | +44 (0)20 7186 8500 |
Carl Sterritt, Chief Executive Officer
| |
Nominated Adviser and Broker Liberum Capital Limited Christopher Britton/Steve Pearce
| +44 (0)20 3100 2222 |
Financial PR Advisor Consilium Strategic Communications | +44 (0)20 3709 5700 shieldtherapeutics@consilium-comms.com |
Mary-Jane Elliott/Matthew Neal |
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) which has exclusive IP rights until 2034. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.
Follow the stocks
